Tag: gynaecology
-
Follow-Up For Patients With Vulval Cancer
Below summarizes the main points for all treatments in accordance to British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: An update on recommendations for practice 2023. Please read the guidelines attached for further details. Patients With Specific Types Of Vulval Cancer – What Are The Key Things To Search For Other Than General Gynaecological Symptoms?…
-
The Structure And Function Of Each Part Of The Female Reproductive System
The Structure And Function Of Each Part Of The Female Reproductive System Polite notice: This page contains diagrams of the reproductive organs of males and females (private parts). It is for educational purposes on cancers that arise in those areas. Please ensure that when visiting the page, there is a sense of manners. We understand…
-
The Structural Layers Of The Female Reproductive System
What Is Histology and The Four Main Types Of Tissue? What Is The Difference Between Cytology And Histology? What Is Immunohistochemistry and How to Perform It? Examples Of Types Of Cells Found In Tissue
-
The Function Of The Female Reproductive System
The Function Of The Female Reproductive System Polite notice: This page contains diagrams of the reproductive organs of males and females (private parts). It is for educational purposes on cancers that arise in those areas. Please ensure that when visiting the page, there is a sense of manners. We understand that in some cultures, there…
-
The role of Cannabis compounds in the treatment of ovarian cancer
Ovarian cancer is one of the most critical health concerns in the female population worldwide. It is the most common gynaecological malignancy, often detected late due to non-specific symptoms at early stages. It has been reported that two of the main bioactive compounds that originate from the Cannabis sativa plant, cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC),…
-
New Monoclonal Antibodies For The Treatment Of Ovarian Cancer
Ovarian cancer presents the highest rate of morbidity and mortality due to its non-specific symptoms in the early stages and its silent nature. Since the invention of hybridoma technology in 1975 by Köhler and Milstein to generate murine monoclonal antibodies, a mass effort was made to design new engineering strategies to maintain demand, efficacy, and…
